CURACRENT REPORT FOR ISSUERS SUBJECT TO THE

1934 ACT REPORTING REQUIREMENTS

FORM 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act

September 2230, 2015

Date of Report

(Date of Earliest Event Reported)

Tianyin Pharmaceutical Co, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-52236

20-4857782

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 ~~(Address of principal executive offices (zip code))~~

(Address of principal executive offices (zip code))

+011-86-28-8551-6696

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))

Section 8 – Other Events

Item 8.01. Other Events

~~Tianyin~~In late September of 2015, Tianyin Pharmaceutical Co., Inc. (the “Company”) iswas ~~currently~~informed ~~actively~~that ~~exploring~~an ~~strategies~~investigation inhad ~~further creating and developing~~been ~~its~~initiated ~~business~~against ~~based~~Dr. ~~upon~~Guoqing ~~the~~Jiang, ~~management’s~~Chief ~~analysis~~Executive onOfficer, ~~the~~Acting ~~current~~Chief ~~market~~Financial ~~trend.~~Officer ~~The~~and ~~market~~Chairman ~~for~~of ~~pharmaceutical~~the ~~products~~Company ~~has~~by Public ~~become~~Order ~~increasingly~~Corps ~~challenging~~of ~~across~~Sichuan ~~the~~Province ~~traditional~~Public ~~Chinese~~Security ~~medicine~~Department (~~TCM~~the “SPPSD”) ~~healthcare~~in ~~industry~~connection ~~due~~with ~~to government policies that raised~~ the ~~costs~~temporary ofhalt of production ~~significantly while restrict~~ and ~~limit~~sale ~~the sales~~ of the ~~TCM~~Company’s ~~products~~Hugan ~~both~~Tablets in ~~pricing~~mid ~~and~~2014, ~~volumes. The net~~which ~~results~~was ofdisclosed ~~such~~in ~~regulatory~~a ~~and~~Current ~~market~~Report ~~environment~~on ~~compress~~Form ~~the~~8-K ~~margins of the TCM business. Our TCM business operations~~filed ~~have been significantly affected~~ by ~~technological stringencies by government regulations as well as intensified market competition in~~ the ~~pharmaceutical~~Company ~~industry.~~on ~~The~~April ~~challenges~~7, ~~range~~2014, ~~from~~amended ~~the~~subsequently ~~heightened~~on ~~stringencies~~May in14, ~~TCM~~2014, ~~extraction~~May ~~purification~~23, ~~plant~~2014 ~~operation, competitive~~and ~~combination~~July ~~products~~8, ~~new~~2014, ~~products~~as ~~offered~~well byas our ~~competitors~~periodic reports thereafter. ~~With~~As ~~constant~~a ~~shifting~~part ~~government~~of ~~policies~~the ~~during recent years~~investigation, ~~severe~~certain ~~price~~files ~~cutting~~of ~~regulations and challenging business operating conditions,~~ the Company ishave ~~currently~~been ~~seeking~~taken ~~strategic investors/companies~~by tothe ~~make and modify business operations including 1) forming strategic alliances with industrial leaders~~SPPSD, ~~2) seeking~~which ~~strategic~~has ~~investors/investment funds, 3) disposing unprofitable operations, and 4) acquiring or merging with healthcare~~caused ~~businesses~~additional ~~that~~delay ~~are~~ in ~~growth phase to create values for our shareholders. The management regards this strategy value adding and necessary for~~ the Company’s toannual ~~grow,~~audit ~~and~~for ~~especially under~~ the ~~unique~~fiscal ~~pharmaceutical~~year ~~business~~ended ~~environment~~June in30, ~~China~~2015.

The Company’s Board of Directors is currently looking into this matter and ascertaining the nature and scope of the investigation. The Company will file an amendment to provide more information once it becomes available.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TIANYIN PHARMACEUTICAL CO., INC.
	By:	/s/Guoqing Jiang
		Name: Dr. Guoqing Jiang
		Name: Guoqing Jiang
		Title: Chief Executive Officer
Dated: September 22, 2015
Dated: October 16, 2015

Filing Compare · TIANYIN PHARMACEUTICAL CO., INC.